[{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M vaccine adjuvant","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Live-attenuated vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Codagenix ","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Codagenix "},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"VPM1002","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ AstraZeneca"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Matrix-M","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Gavi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Gavi","highestDevelopmentStatusID":"8","companyTruncated":"Serum Institute of India \/ Gavi"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Beximco Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Beximco Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Beximco Pharma"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"SpyBiotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"Virus-like-particle vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"7","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ AstraZeneca"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"8","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"CDX-005","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Codagenix","highestDevelopmentStatusID":"4","companyTruncated":"Serum Institute of India \/ Codagenix"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"ABEC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"8","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Government of Bangladesh","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Government of Bangladesh","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Government of Bangladesh"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVI-VAC","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal drops","sponsorNew":"Serum Institute of India \/ Serum Institute","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ Serum Institute"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"10-Valent Pneumococcal Conjugate Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Live-attenuated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal drops","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ AstraZeneca","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ AstraZeneca"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Memo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"MTX-COVAB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"4","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Inactivated Salk Polio Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ChAdOx1 nCoV-19","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Novavax","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Novavax"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Matrix-M1","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"GreenLight Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Licensing Agreement","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"3","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Serum Institute","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Serum Institute"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Novavax","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Matrix-M","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"NVX-COV2373","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Tetravalent HPV Vaccine","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Quadrivalent Human Papillomavirus Vaccine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ChAdOx1 biEBOV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ University of Oxford","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ University of Oxford"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Live-attenuated Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"10","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SOUTH AFRICA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"10 Valent Pneumococcal Polysaccharide Conjugate Vaccine","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BCG Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"NVX-CoV2373","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Capsid L1 Virus-like Particle","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Series B Financing","leadProduct":"CodaVax-RSV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Matrix-M","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Nogapendekin Alfa Inbakicept","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Live Attenuated Tetravalent Dengue Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Serum Institute of India \/ Not Applicable"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Hervolution Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"IPT-001","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Serum Institute of India","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"5","companyTruncated":"Serum Institute of India \/ Serum Institute of India"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Primrose Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Serum Institute of India \/ Serum Institute of India","highestDevelopmentStatusID":"3","companyTruncated":"Serum Institute of India \/ Serum Institute of India"}]

Find Clinical Drug Pipeline Developments & Deals by Serum Institute of India

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : The companies will contribute towards the design of the vaccine with Primrose fully responsible for developing strains using its Pfenex Technology and SIIPL responsible for further commercialization.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 10, 2025

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Recipient : Primrose Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : The financing will support the company-lead product IPT-001 to advance the clinical development for the treatment of HERVs prostate and pancreatic cancer.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          December 19, 2024

                          Lead Product(s) : IPT-001

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : Hervolution Therapeutics

                          Deal Size : $11.7 million

                          Deal Type : Series A Financing

                          blank

                          03

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Dengusiil is a tetravalent live attenuated dengue vaccine, which is being developed for the treatment of dengue.

                          Product Name : Dengusiil

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          June 06, 2024

                          Lead Product(s) : Live Attenuated Tetravalent Dengue Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Through the agreement, the companies will concentrate on scaling up the manufacture of BCG for use in combination with Anktiva (Nogapendekin Alfa Inbakicept) for non-muscle invasive bladder cancer.

                          Product Name : Anktiva

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 02, 2024

                          Lead Product(s) : Nogapendekin Alfa Inbakicept,Recombinant Bacillus Calmette-Guerin

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Recipient : ImmunityBio

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Covovax (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COV...

                          Product Name : Covovax

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          April 10, 2023

                          Lead Product(s) : NVX-COV2373,Matrix-M

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Covovax (NVX-COV2373), is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization and is seeking inclusion of covovax on CoWIN as heterologous booster dose for a...

                          Product Name : Covovax

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          April 03, 2023

                          Lead Product(s) : NVX-COV2373,Matrix-M

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Proceeds from the financing will support the clinical development of CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV) disease.

                          Product Name : CodaVax-RSV

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          February 15, 2023

                          Lead Product(s) : CodaVax-RSV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Recipient : Codagenix

                          Deal Size : $25.0 million

                          Deal Type : Series B Financing

                          blank

                          08

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) ‘CERVAVAC’ is an outcome of a partnership between Serum Institute Of India (SII), Department of Biotechnology and the BIRAC, along with the Bill and Melinda Gates...

                          Product Name : Cervavac

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 25, 2023

                          Lead Product(s) : Capsid L1 Virus-like Particle

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Covovax (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COV...

                          Product Name : Covovax

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 18, 2023

                          Lead Product(s) : NVX-COV2373,Matrix-M

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          PharmScience R&D
                          Not Confirmed
                          PharmScience R&D
                          Not Confirmed

                          Details : Covovax (NVX-COV2373) is a spike protein nanoparticle vaccine, manufactured through technology transfer from Novavax. It has been approved for marketing authorization as a booster dose for adults who have been administered two doses of covishield or cova...

                          Product Name : Covovax

                          Product Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 16, 2023

                          Lead Product(s) : NVX-COV2373,Matrix-M

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank